Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Treatment Landscape Evolutions

Subscribe

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

Articles

According to the company, the MHRA approval represents the first marketing approval outside the US for NAI. 

UK’s MHRA approves nogapendekin alfa inbakicept plus BCG in NMIBC

Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks. 

Enrollment complete for phase 3 UTOPIA trial in LG-IR-NMIBC

The data, collected as part of the phase 1/2 Duravelo-1 trial, showed an objective response rate of 65%.

Zelenectide pevedotin plus pembrolizumab shows promising anti-tumor activity in mUC

For the trial, a biomarker will be utilized to aid in patient selection for the treatment.

FDA and EMA authorize phase 3 trial of masitinib for mCRPC

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times – News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

Exploring Treatment Approaches for Advanced Prostate Cancer

Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR Alteration

Videos

Panelists review four 4 clinical cases, discussing guideline-directed approaches to new and emerging treatment approaches in patients with hormone-sensitive and castration-resistant prostate cancer, as well as share sharing perspectives on key clinical trial data that may impact our decisions.

Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is managed with a combination of androgen deprivation therapy, chemotherapy, and novel agents like such as abiraterone and enzalutamide, aiming to improve survival outcomes while addressing the disease's high metastatic burden.

Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Overview

Panelists discuss how the management of metastatic castration-sensitive prostate cancer involves a multidisciplinary approach, utilizing androgen deprivation therapy, chemotherapy, and novel agents to control disease progression and improve patient survival.

Case 1: Metastatic Castration- Sensitive Prostate Cancer (mCSPC)

Panelists discuss how the management of low-volume recurrent metastatic castration-sensitive prostate cancer (mCSPC) focuses on personalized treatment strategies, including the use of androgen deprivation therapy and targeted therapies, to achieve optimal outcomes while minimizing treatment-related toxicity.

Case 2: Low-Volume Recurrent mCSPC

Panelists discuss how the management of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence involves careful monitoring and the potential use of novel therapies, such as androgen receptor inhibitors, to delay progression and improve patient outcomes.

Case 3: Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence

Panelists discuss how the management of metastatic castration-resistant prostate cancer with a homologous recombination repair (HRR) alteration involves targeted therapies, such as PARP inhibitors, to exploit the genetic vulnerability and improve treatment response.

I'm sorry, but it seems there is no article provided for me to summarize and extract key takeaways from. Could you please provide the text of the article

Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR Alteration

EP: 1.Metastatic Castration-Sensitive Prostate Cancer (mCSPC) Overview

EP: 2.Case 1: Metastatic Castration- Sensitive Prostate Cancer (mCSPC)

EP: 3.Case 2: Low-Volume Recurrent mCSPC

EP: 4.Case 3: Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence

EP: 5.Case 4: Metastatic Castration-Resistant Prostate Cancer With an HRR Alteration

Newsletter